Xilio Therapeutics (XLO) files $250M mixed shelf May 12, 2026 07:57AM
Xilio Therapeutics reports Q4 2025 results, extends cash runway to 2027 Mar 23, 2026 07:31AM
Xilio Therapeutics prices $40 million offering of pre-funded warrants Feb 12, 2026 05:19AM
Xilio receives $35.8 million from warrant exercises, extends cash runway Jan 8, 2026 08:37AM
Xilio Therapeutics, Inc. (XLO) Misses Q3 EPS by 6c Nov 13, 2025 05:02PM


Nov 7, 2025 09:02AM Xilio presents preclinical data on masked immunotherapy programs at SITC
Aug 6, 2025 06:19AM Leerink Partners Starts Xilio Therapeutics Inc (XLO) at Outperform, PT $2
Jun 10, 2025 04:30PM Xilio Therapeutics (XLO) Appoints Akintunde Bello to its Board
Jun 2, 2025 08:47AM Xilio Therapeutics (XLO) Announces Pricing of $50.0 Million Public Offering
Jun 2, 2025 06:13AM Xilio Therapeutics (XLO) Announces Proposed Public Offering
May 8, 2025 05:22PM Xilio Therapeutics, Inc. (XLO) Misses Q1 EPS by 37c
Mar 11, 2025 07:32AM Xilio Therapeutics (XLO) Announces Pipeline and Business Updates, Reports Q4
Feb 12, 2025 07:31AM AbbVie (ABBV) and Xilio Therapeutics (XLO) Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Jan 21, 2025 05:05PM Xilio Therapeutics (XLO) Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colo
Dec 16, 2024 07:31AM Xilio Therapeutics (XLO) Appoints Caroline Hensley as Chief Legal Officer
Nov 7, 2024 09:15AM Xilio Therapeutics (XLO) Reports Initial Trial Data from Phase 1C Dose Escalation for Vilastobart
Nov 7, 2024 09:06AM Xilio Therapeutics (XLO) Issues Q3 Pipeline and Business Updates
Aug 20, 2024 08:15AM TD Cowen Reiterates Buy Rating on Xilio Therapeutics Inc (XLO)
Aug 8, 2024 08:55AM Xilio Therapeutics, Inc. (XLO) Misses Q2 EPS by 1c
Jun 13, 2024 04:09PM Xilio Therapeutics (XLO) Appoints Aoife Brennan and James Shannon to its Board